111 related articles for article (PubMed ID: 35660809)
1. PD-L1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome.
Wang L; Liu H
Ann Diagn Pathol; 2022 Oct; 60():151976. PubMed ID: 35660809
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma.
Ledderose S; Schulz H; Paul T; Ledderose C; Ledderose GJ
Pathol Res Pract; 2023 Jan; 241():154289. PubMed ID: 36584498
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
4. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
Liu HQ; Zou BQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
[No Abstract] [Full Text] [Related]
5. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
7. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
12. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
13. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma.
Ledderose S; Ledderose C; Penkava J; Ledderose GJ
Laryngoscope; 2022 Jul; 132(7):1334-1339. PubMed ID: 34415055
[TBL] [Abstract][Full Text] [Related]
15. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
[TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
